SCHEMBL542299

SCHEMBL542299

CC(=O)NNC(C)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.36
SLC7A5 Q01650 1/20 0.36
KDM4E B2RXH2 2/20 0.33
NFKB1 P19838 2/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX5 P09917 1/20 0.33
TSHR P16473 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
ALOX15 P16050 1/20 0.33
PTGS2 P35354 1/20 0.33
THPO P40225 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
RAB9A P51151 1/20 0.32
MME P08473 1/20 0.32
ACE P12821 1/20 0.32
CPA1 P15085 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL542297 1.00 ALDH1A1 (0.37) ALDH1A1TP53SLC7A5KDM4ENFKB1
SCHEMBL3416543 0.77 SLC7A5 (0.40) TP53SLC7A5NFKB1CYP3A4TSHR
SCHEMBL3416544 0.77 SLC7A5 (0.40) TP53SLC7A5NFKB1CYP3A4TSHR
SCHEMBL10408938 0.77 SLC7A5 (0.40) TP53SLC7A5NFKB1CYP3A4TSHR
SCHEMBL8604228 0.77 TP53 (0.35) TP53SLC7A5RAB9AMMEACE
SCHEMBL2555426 0.77 TGFBR1 (0.42) ALDH1A1TP53SLC7A5KDM4E
SCHEMBL12481867 0.77 TGFBR1 (0.42) ALDH1A1TP53SLC7A5KDM4E
SCHEMBL1485441 0.75
SCHEMBL6756485 0.73 SLC7A5 (0.37) TP53SLC7A5
SCHEMBL6756484 0.73 SLC7A5 (0.37) TP53SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-58174586-A None JP disclosed
US-20250154219-A1 PEPTIDE ANALOGS ADEPTHERA LLC 2025-05-15 US disclosed
US-12110318-B2 Peptide analogs ADEPTHERA LLC (US) 2024-10-08 US disclosed
US-20220324935-A1 PEPTIDE ANALOGS ADEPTHERA LLC 2022-10-13 US disclosed
US-11390657-B2 Peptide analogs ADEPTHERA LLC (US) 2022-07-19 US disclosed
US-20200339649-A1 PEPTIDE ANALOGS ADEPTHERA LLC 2020-10-29 US disclosed
CN-106999540-B Combination therapy 比格基因有限公司 2020-10-27 CN disclosed
EP-3645031-A1 PEPTIDE ANALOGS Adepthera LLC (US) 2020-05-06 EP disclosed
US-10328116-B2 Combinations of proteasome inhibitors and cyclic peptides BIG DNA LTD (GB) 2019-06-25 US disclosed
US-20190175687-A1 Combination Therapy BIG DNA LTD (GB) 2019-06-13 US disclosed
EP-0836383-A1 COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1998-04-22 EP disclosed
WO-1997045412-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1997-12-04 WO disclosed
WO-1997038664-A2 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1997-10-23 WO disclosed
WO-1997036587-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1997-10-09 WO disclosed
US-5661161-A Inhibitors of farnesyl-protein transferase MERCK & CO., INC. (US) 1997-08-26 US disclosed
EP-0783518-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO. INC. (US) 1997-07-16 EP disclosed
WO-1997002817-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS UNIVERSITY OF CINCINNATI (US) 1997-01-30 WO disclosed
WO-1997001275-A1 COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-01-16 WO disclosed
WO-1996010035-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1996-04-04 WO disclosed
JP-S58174586-A PREPARATION OF DL-SERINE TANABE SEIYAKU CO LTD 1983-10-13 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339649-A1 PEPTIDE ANALOGS RAMP1, RAMP2, RAMP3 ALDH1A1 4707/4885TP53 4851/4885SLC7A5 2067/4885
US-12110318-B2 Peptide analogs RAMP1, RAMP3, RAMP2 ALDH1A1 4712/4885TP53 4817/4885SLC7A5 1526/4885
US-20220324935-A1 PEPTIDE ANALOGS RAMP1, RAMP2, RAMP3 ALDH1A1 4707/4885TP53 4851/4885SLC7A5 2067/4885
US-10328116-B2 Combinations of proteasome inhibitors and cyclic peptides PSMB3, PSMA3, PSMA6 ALDH1A1 1474/4885TP53 2308/4885SLC7A5 3807/4885
US-20250154219-A1 PEPTIDE ANALOGS RAMP1, RAMP2, RAMP3 ALDH1A1 4707/4885TP53 4851/4885SLC7A5 2067/4885
US-20190175687-A1 Combination Therapy PSMA6, PSMB3, PSMB6 ALDH1A1 1272/4885TP53 2287/4885SLC7A5 3805/4885
US-11390657-B2 Peptide analogs RAMP1, RAMP3, RAMP2 ALDH1A1 4712/4885TP53 4817/4885SLC7A5 1526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.